• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

In vitro thymidine labelling index in primary operable breast cancer.

作者信息

Holt S, Croton R, Leinster S J, McDicken I, Nicholson R I, Cooke T G, George W D

出版信息

Eur J Surg Oncol. 1986 Mar;12(1):53-7.

PMID:3956755
Abstract

The in vitro Thymidine Labelling Index (TLI) of 164 primary breast carcinoma was measured. The relationship of TLI to other established prognostic variables was examined, and the rates of of recurrence and survival of groups of women with high and low TLI tumours were compared. Poorly differentiated tumours had significantly greater TLI values but there were no significant associations with tumour size, axillary lymph node status, age and menopausal status or steroid receptor status. Although there were more recurrences and deaths in the group of women with high TLI tumours, these differences were not statistically significant. In vitro TLI may be a further expression of tumour differentiation, rather than cellular proliferation, and from this study does not provide any additional prognostic information.

摘要

相似文献

1
In vitro thymidine labelling index in primary operable breast cancer.
Eur J Surg Oncol. 1986 Mar;12(1):53-7.
2
DNA ploidy and TLI in association with other prognostic parameters in breast cancer.
Anticancer Res. 1999 Jan-Feb;19(1A):381-4.
3
In vitro DNA synthesis in freshly separated human breast cancer cells assessed by tritiated thymidine incorporation assay: relationship to the long-term outcome of patients.通过氚标记胸腺嘧啶核苷掺入试验评估新鲜分离的人乳腺癌细胞中的体外DNA合成:与患者长期预后的关系。
Br J Surg. 1999 Nov;86(11):1463-9. doi: 10.1046/j.1365-2168.1999.01248.x.
4
259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.应用USC/范纽斯预后指数的259例乳腺导管原位癌患者:长期随访的回顾性研究
Breast Cancer Res Treat. 2008 Jun;109(3):405-16. doi: 10.1007/s10549-007-9668-7. Epub 2007 Aug 9.
5
Reliability and stability of the thymidine labeling index of breast carcinoma.乳腺癌胸腺嘧啶标记指数的可靠性与稳定性
Lab Invest. 1986 Feb;54(2):160-4.
6
Molecular markers for prognosis after isolated postmastectomy chest wall recurrence.单纯乳房切除术后胸壁复发预后的分子标志物
Cancer. 2004 Jan 15;100(2):252-63. doi: 10.1002/cncr.11915.
7
Cell kinetics in selection and stratification of patients for adjuvant therapy of breast carcinoma.乳腺癌辅助治疗患者选择与分层中的细胞动力学
NCI Monogr. 1986(1):25-8.
8
Advanced stage and early relapse of breast carcinomas associated with high thymidine labeling indices.
Cancer Res. 1979 Oct;39(10):4042-7.
9
[The labelling index as a prognostic marker in breast carcinoma].[标记指数作为乳腺癌的预后标志物]
Minerva Med. 1994 Apr;85(4):141-4.
10
[Does primary tumor affect the prognosis in postmastectomy locoregional recurrence in breast carcinoma?].[原发性肿瘤对乳腺癌乳房切除术后局部区域复发的预后有影响吗?]
Strahlenther Onkol. 1995 Jan;171(1):18-28.

引用本文的文献

1
The potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signalling.环境中的化学混合物促成持续增殖信号传导这一癌症标志的可能性。
Carcinogenesis. 2015 Jun;36 Suppl 1(Suppl 1):S38-60. doi: 10.1093/carcin/bgv030.
2
Thymidine labeling index in breast tumors.乳腺肿瘤中的胸苷标记指数。
Jpn J Surg. 1990 Mar;20(2):180-5. doi: 10.1007/BF02470766.